To present data on XEN-45 gel stent implantation for the treatment of refractory secondary glaucoma (SG) in a Chinese patient population, highlighting its significance in improving patient outcomes.
Key Findings:
XEN-45 gel stents effectively manage various forms of refractory secondary glaucoma, with a reported success rate of X%.
The ab externo implantation techniques resulted in minimal intraocular manipulation and rapid recovery, with a complication rate of Y%.
The study included diverse SG cases, enhancing the understanding of XEN-45's applicability across different patient demographics.
Interpretation:
The XEN-45 gel stent is a promising minimally invasive option for patients with refractory secondary glaucoma, potentially reducing complications associated with traditional surgeries, such as hypotony and bleb leaks.
Limitations:
The study's sample size and follow-up duration may limit the generalizability of the findings, particularly in diverse populations.
Comparative analyses with other surgical techniques were not included, which may affect the robustness of the conclusions drawn.
Conclusion:
XEN-45 gel stent implantation is a viable treatment for refractory secondary glaucoma, offering a safer alternative to traditional surgical methods, with implications for improving patient management strategies.
Thomas Aller, OD, provides in-depth overviews of each myopia management option—pharmacologic therapy, soft contact lenses, orthokeratology, spectacle lenses, and environmental and behavioral interventions—so clinicians can not only provide the right option to each patient, but also address the larger economic and societal burdens of myopia.
